7,457 Danaher Corporation $DHR Shares Sold by Woodley Farra Manion Portfolio Management Inc.

Woodley Farra Manion Portfolio Management Inc. lessened its holdings in Danaher Corporation (NYSE:DHR) by 2.7% during the third quarter, HoldingsChannel.com reports. The fund owned 269,789 shares of the conglomerate’s stock after selling 7,457 shares during the quarter. Danaher makes up about 3.0% of Woodley Farra Manion Portfolio Management Inc.’s portfolio, making the stock its 12th biggest holding. Woodley Farra Manion Portfolio Management Inc.’s holdings in Danaher were worth $59,875,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in DHR. Prime Capital Investment Advisors LLC lifted its stake in shares of Danaher by 0.5% during the third quarter. Prime Capital Investment Advisors LLC now owns 9,203 shares of the conglomerate’s stock worth $2,039,000 after purchasing an additional 45 shares in the last quarter. Essential Investment Partners LLC grew its stake in shares of Danaher by 34.6% in the third quarter. Essential Investment Partners LLC now owns 175 shares of the conglomerate’s stock valued at $39,000 after buying an additional 45 shares in the last quarter. Montis Financial LLC grew its stake in shares of Danaher by 2.3% in the third quarter. Montis Financial LLC now owns 2,020 shares of the conglomerate’s stock valued at $448,000 after buying an additional 46 shares in the last quarter. Covestor Ltd raised its holdings in shares of Danaher by 28.3% during the 3rd quarter. Covestor Ltd now owns 213 shares of the conglomerate’s stock valued at $47,000 after buying an additional 47 shares during the period. Finally, Veery Capital LLC raised its holdings in shares of Danaher by 3.1% during the 3rd quarter. Veery Capital LLC now owns 1,581 shares of the conglomerate’s stock valued at $350,000 after buying an additional 48 shares during the period. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Analyst Upgrades and Downgrades

DHR has been the topic of a number of recent research reports. The Goldman Sachs Group reissued a “buy” rating and set a $275.00 target price on shares of Danaher in a research report on Thursday, October 22nd. Wells Fargo & Company lowered their price target on shares of Danaher from $212.00 to $195.00 and set an “equal weight” rating for the company in a report on Wednesday, July 22nd. Citigroup lifted their price target on shares of Danaher from $230.00 to $270.00 and gave the stock a “buy” rating in a research note on Thursday, October 22nd. Morgan Stanley boosted their price objective on shares of Danaher from $220.00 to $240.00 and gave the stock an “overweight” rating in a report on Monday, October 12th. Finally, Wall Street Zen upgraded shares of Danaher from a “hold” rating to a “buy” rating in a report on Monday, October 26th. Eighteen investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $242.91.

Danaher Stock Performance

Shares of DHR stock opened at $236.41 on Wednesday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.29 and a current ratio of 1.63. Danaher Corporation has a one year low of $160.93 and a one year high of $242.80. The company’s 50-day simple moving average is $221.10 and its 200-day simple moving average is $201.55. The stock has a market capitalization of $166.32 billion, a price-to-earnings ratio of 38.69, a PEG ratio of 2.95 and a beta of 0.76.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Wednesday, October 21st. The conglomerate reported $2.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.92 by $0.19. Danaher had a return on equity of 11.17% and a net margin of 16.91%. The business had revenue of $6.55 billion for the quarter, compared to analyst estimates of $6.56 billion. During the same period in the prior year, the company posted $1.89 EPS. The business’s revenue was up 8.3% compared to the same quarter last year. Equities analysts anticipate that Danaher Corporation will post 8.59 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th were given a $0.40 dividend. The ex-dividend date was Wednesday, September 30th. This represents a $1.60 annualized dividend and a yield of 0.7%. Danaher’s dividend payout ratio is 26.19%.

Insider Activity

In other Danaher news, EVP Gregory M. Milosevich sold 2,100 shares of the firm’s stock in a transaction dated Monday, November 9th. The shares were sold at an average price of $230.62, for a total transaction of $484,302.00. Following the transaction, the executive vice president owned 22,367 shares of the company’s stock, valued at approximately $5,158,277.54. This trade represents a 8.58% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Christopher Bouda sold 7,598 shares of the firm’s stock in a transaction that occurred on Wednesday, October 28th. The shares were sold at an average price of $234.56, for a total transaction of $1,782,186.88. Following the transaction, the chief accounting officer owned 9,107 shares in the company, valued at $2,136,137.92. This represents a 45.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 10.80% of the stock is currently owned by corporate insiders.

About Danaher

Danaher is a global science and technology company that develops and supplies products and services for biotechnology, life sciences, and diagnostics markets. Its offerings include instruments, reagents, consumables, software, and services used in research, drug development and manufacturing, and clinical testing. The company’s businesses include well-known brands such as Cytiva and Pall in bioprocessing and filtration, Beckman Coulter in laboratory and clinical diagnostics, Cepheid in molecular diagnostics, and Leica Microsystems in microscopy.